TY  - JOUR
AU  - Kapp-Schwoerer, Silke
AU  - Weber, Daniela
AU  - Corbacioglu, Andrea
AU  - Gaidzik, Verena I
AU  - Paschka, Peter
AU  - Krönke, Jan
AU  - Theis, Frauke
AU  - Rücker, Frank G
AU  - Teleanu, Maria-Veronica
AU  - Panina, Ekaterina
AU  - Jahn, Nikolaus
AU  - Herzig, Julia K
AU  - Kubanek, Lena
AU  - Schrade, Anika
AU  - Gohring, Gudrun
AU  - Fiedler, Walter
AU  - Kindler, Thomas
AU  - Schroeder, Thomas
AU  - Mayer, Karin
AU  - Lübbert, Michael
AU  - Wattad, Mohammed
AU  - Götze, Katharina
AU  - Horst, Heinz A
AU  - Koller, Elisabeth
AU  - Wulf, Gerald G
AU  - Schleicher, Jan
AU  - Bentz, Martin
AU  - Krauter, Jürgen
AU  - Bullinger, Lars
AU  - Krzykalla, Julia
AU  - Benner, Axel
AU  - Schlenk, Richard F
AU  - Thol, Felicitas
AU  - Heuser, Michael
AU  - Ganser, Arnold
AU  - Döhner, Hartmut
AU  - Döhner, Konstanze
TI  - Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1 mutated AML patients: results from the AMLSG 09-09 Trial.
JO  - Blood
VL  - 136
IS  - 26
SN  - 1528-0020
CY  - Stanford, Calif.
PB  - HighWire Press
M1  - DKFZ-2020-01703
SP  - 3041-3050
PY  - 2020
N1  - 2020 Dec 24;136(26):3041-3050
AB  - Monitoring of measurable residual disease (MRD) provides prognostic information in patients with Nucleophosmin1 mutated (NPM1mut) acute myeloid leukemia (AML) and represents a powerful tool to evaluate treatment effects within clinical trials. We determined NPM1mut transcript levels (TL) by RQ-PCR and evaluated the prognostic impact of NPM1mut MRD and the effect of gemtuzumab ozogamicin (GO) on NPM1mut TL and the cumulative incidence of relapse (CIR) in patients with NPM1mut AML enrolled in the randomized phase III AMLSG 09-09 trial. 3733 bone marrow (BM) and 3793 peripheral blood (PB) samples from 469 patients were analyzed. NPM1mut TL log10 reduction ≥3 and achievement of MRD negativity in BM and PB were significantly associated with a lower CIR rate, after two treatment cycles and at end of treatment (EOT). In multivariate analyses, MRD positivity consistently revealed as poor prognostic factor in BM and PB. With regard to treatment effect, the median NPM1mut TL were significantly lower in the GO-Arm across all treatment cycles, resulting in a significantly higher proportion of patients achieving MRD negativity at EOT (56
LB  - PUB:(DE-HGF)16
C6  - pmid:32812041
DO  - DOI:10.1182/blood.2020005998
UR  - https://inrepo02.dkfz.de/record/157548
ER  -